Free Cash Flow

Professor Youmin Xi's recent honor signals more than academic success. It marks a strategic blueprint for cultivating the next generation of life science leaders.

Husqvarna unveils a massive cost-cutting plan alongside ambitious growth and green targets. Can this strategic pivot secure its future market leadership?

Hexagon Purus erases a $12.9M debt in its Panasonic battery deal but gives up lucrative US tax credits, a move securing its supply chain at a high cost.

Following stellar clinical data, Terns Pharmaceuticals' upsized $650M offering signals massive investor confidence and funds its push to disrupt the CML market.

Gossamer Bio's recent 200,000-share grant to a new hire is more than a welcome bonus; it's a strategic bet on its blockbuster drug candidate.

A prestigious Yale recognition for board member Dr. Curtis Patton bolsters Tevogen's credibility as it advances its AI and T-cell platforms.

A $15 million donation from Publix Charities confronts the Southeast's housing crisis, blending a legacy of giving with a critical modern-day need.

A routine regulatory filing reveals First Trust's 4.99% stake in NCC Group, fueling speculation around the struggling cybersecurity firm's future.

A modest SEK 1.5 million order may not turn heads, but for Cell Impact, it's a critical validation that could unlock mass production in the booming Asian FCEV market.

With its 2026 Investor Day nearing, PHINIA aims to prove its dual-path strategy is the key to powering a diverse, carbon-conscious industrial future.

Led by a controversial figure, AlphaTON Capital pitches a bold Web3 vision in Abu Dhabi, but its grand ambitions clash with stark financial realities.

Clene Inc. heads to an investor conference with powerful new ALS data. But with a limited cash runway, the real test is securing market confidence.

Century Therapeutics adds M&A and investment heavyweights to its board, a strategic move to navigate the clinical gauntlet with its iPSC-derived diabetes cure.

TransAlta is converting a massive coal plant to natural gas, a pragmatic yet controversial move in the push for a cleaner, reliable energy future.

The space tourism pioneer is restructuring its debt, buying precious time for its next-gen fleet but at a steep cost for shareholders and future finances.

Insiders at the newly independent Magnum Ice Cream Company show major confidence with multi-million-euro share buys following its spin-off from Unilever.

Broadway star Morgan Dudley returns to the tech platform that discovered her, a high-stakes move for Stargaze's bid to reshape talent discovery.

Following a major clinical trial win, Kymera Therapeutics seeks $500M. We break down the high-stakes strategy behind funding a new era of medicine.

SRN Advisors is consolidating its dividend ETFs, shifting from a defensive strategy to pure growth and highlighting a major consolidation trend in finance.

Protara Therapeutics secured a $75M offering to advance its promising cancer drug, TARA-002, signaling renewed investor confidence in biotech innovation.